Asset Details
Do you wish to reserve the book?
Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus
Do you wish to request the book?
Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti-CD19 chimeric antigen receptor T cells in Evans syndrome of systemic lupus erythematosus
2026
Overview
Evans syndrome, characterized by autoimmune hemolytic anemia and immune thrombocytopenia, is rare and often refractory to conventional therapies. In Chinese patients with systemic lupus erythematosus (SLE), its incidence is approximately 0.47%. We report the first case of anti-CD19 chimeric antigen receptor (CAR) T cell therapy for SLE-Evans syndrome. A 36-year-old woman with refractory disease received autologous CD19 CAR T cells (inati-cel) after lymphodepleting chemotherapy. CAR T cells expanded rapidly, peaking on day 7, and remained detectable for 6 months. CD19 B cells were eliminated by day 14. Hemoglobin levels improved from 48 g/L pre-infusion to 115 g/L at day 28 and stabilized. Platelet counts increased from 60,000/µL to 195,000/µL at 2 months. Only grade 1 cytokine release syndrome occurred, with no other adverse events. This case demonstrates that CD19 CAR T cell therapy is a promising approach for refractory Evans syndrome, warranting further investigation.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V,Springer
Subject
/ Anemia
/ Anemia, Hemolytic, Autoimmune - blood
/ Anemia, Hemolytic, Autoimmune - immunology
/ Anemia, Hemolytic, Autoimmune - therapy
/ Antigens
/ Consent
/ Disease
/ Female
/ Funding
/ Humans
/ Immunotherapy, Adoptive - methods
/ Lupus
/ Lupus Erythematosus, Systemic - complications
/ Lupus Erythematosus, Systemic - therapy
/ Medicine
/ Oncology
/ Patients
/ Receptors, Chimeric Antigen - immunology
/ Systemic lupus erythematosus
/ T-Lymphocytes - transplantation
